Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights
Provided By GlobeNewswire
Last update: Aug 5, 2025
BBI-355 and BBI-825 combination arm of the POTENTIATE trial is now open for enrollment
BBI-940 is on track for submission of an investigational new drug application in the first half of 2026
Read more at globenewswire.com
